|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla).
|
26687706 |
2016 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
Dalcetrapib increased high-density lipoprotein cholesterol (HDL-C) and ApoA1 levels to a similar extent in FHA (+22.8, +13.9%) and FCH (+18.4, +12.1%), both p < 0.001 vs. placebo.
|
25281277 |
2014 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
These observations show that mutations in ABCA1, APOA1, and LCAT are sufficient to explain >40% of familial hypoalphalipoproteinemia in this cohort.
|
21875686 |
2012 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
To determine the frequency of familial hypoalphalipoproteinemia in the general population due to mutation of the apolipoprotein A-I (apo A-I) gene, we analyzed sequence variations in the apo A-I gene.
|
9931341 |
1999 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GermlineCausalMutation
|
disease |
ORPHANET |
Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia.
|
8282791 |
1994 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GermlineCausalMutation
|
disease |
ORPHANET |
The data suggest that a part of familial hypoalphalipoproteinemia might be an autosomal dominant trait due to a completely defective apolipoprotein A-I gene.
|
8240372 |
1993 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A-I metabolism in subjects with a PstI restriction fragment length polymorphism of the apoA-I gene and familial hypoalphalipoproteinemia.
|
1981893 |
1990 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia.
|
3081805 |
1986 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The ApoA-1 Synthesis Stimulation and intravascular Ultrasound for coronary atheroma Regression Evaluation (ASSURE; NCT01067820) study employed serial intravascular ultrasound (IVUS) measures of coronary atheroma in 281 patients treated with apabetalone or placebo for 26 weeks.
|
30155718 |
2019 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study suggested that T2DM, Lp(a), HDL-c, and ApoA1 were risk factors of CAD and that the IL-17A rs2275913 and IL-23R rs6682925 polymorphisms may contribute to susceptibility to CAD.
|
31074535 |
2019 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the levels of lncRNA KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1), hypoxia-inducible factor 1 alpha-antisense RNA 2 (HIF1A-AS2) and apolipoprotein A-1 antisense RNA (APOA1-AS) were significantly increased in CAD patients (KCNQ1OT1 increased by 2.38-fold, P = 0.00042; HIF1A-AS2 increased by 2.00-fold, P = 0.0001; APOA1-AS increased by 4.52-fold, P = 0.000048).
|
30941792 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies in the human hepatocarcinoma line HepG2 also showed AFB1-exposure to increase ApoA1, LDL, TC, and TG contents; induce cell proliferation; and reduce hepatocellular AKR7A expression.
|
31376682 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid deposits of WT apolipoprotein A-I (apoA-I), the main protein component of high-density lipoprotein, accumulate in atherosclerotic plaques where they may contribute to coronary artery disease by increasing plaque burden and instability.
|
29853648 |
2018 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid deposits of WT apolipoprotein A-I (apoA-I), the main protein component of high-density lipoprotein, accumulate in atherosclerotic plaques where they may contribute to coronary artery disease by increasing plaque burden and instability.
|
29853648 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Significant relationships between the ApoA-I level and OS were specifically detected in nasopharyngeal carcinoma (NPC, HR = 0.63, 95% CI: 0.54-0.73), colorectal cancer (CRC, HR = 0.48, 95% CI: 0.19-0.76), and hepatocellular carcinoma (HCC, HR = 0.46, 95% CI: 0.27-0.65).
|
30510601 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockdown of frataxin by > 70% in human hepatoma HepG2 cells caused a 20% reduction in secreted ApoA-I.
|
29447225 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to propose a prognostic scoring system based on preoperative serum apolipoprotein A-1 and C-reactive protein (ApoA-1 and CRP, AC score) levels and to evaluate the prognostic value of these markers in patients with hepatocellular carcinoma (HCC).
|
30486825 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A1 polymorphisms and risk of coronary artery disease: a meta-analysis.
|
28721149 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population.
|
29074586 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.
|
28775061 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Wild-type apoA-I protein was compared to human variants that either are protective (R173C, Milano) or lead to increased risk for ischaemic heart disease (A164S).
|
29051568 |
2017 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In fact, a significant increase of plasmatic triglycerides (TG) level, atherogenic lipid ratios (TC/HDL-C,TG/HDL-C, LDL-C/HDL-C); and ApoB/ApoA1 was observed in the CAD group comparatively to controls (p < 0.001).
|
28806974 |
2017 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A stronger association between APOA1-75G/A polymorphisms and CAD risk was present in the studies consistent with HWE.
|
28721149 |
2017 |